- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Col1a2.
Displaying page 1 of 1.
EudraCT Number: 2015-003699-60 | Sponsor Protocol Number: KIBB01 | Start Date*: 2018-09-28 |
Sponsor Name:Karolinska Institutet | ||
Full Title: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal... | ||
Medical condition: Treatment of Osteogenesis Imperfecta (OI) type III and severe type IV. | ||
Disease: | ||
Population Age: In utero, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002887-29 | Sponsor Protocol Number: Uni-Koeln-1574 | Start Date*: 2013-02-13 |
Sponsor Name:University of Cologne | ||
Full Title: Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab | ||
Medical condition: In this study we will evaluate the efficacy of Denosumab in children with Osteogenesis imperfecta. Subjects will be treated every 12 weeks over 36 weeks with Denosumab 1mg/kg body weight s.c.. Effi... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002553-38 | Sponsor Protocol Number: TERCELOI | Start Date*: 2013-08-09 |
Sponsor Name:Itziar Astigarraga Aguirre | ||
Full Title: Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfecta | ||
Medical condition: Osteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe ... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006597-23 | Sponsor Protocol Number: UX143-CL301 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta. | |||||||||||||
Medical condition: Osteogenesis imperfecta (OI) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DK (Prematurely Ended) DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
